First-in-Human Single and Multiple Dose of GLPG1837

NCT02325037 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GLPG1837 single ascending doses
DRUG: Placebo single dose
DRUG: GLPG1837 multiple ascending doses
DRUG: Placebo multiple doses

Sponsor

Lakefront Biotherapeutics NV